CAC Score: What Your Coronary Calcium Number Changes About Your Treatment

What a CAC Score Actually Measures

The coronary artery calcium score quantifies calcified atherosclerotic plaque in all four major coronary arteries using a low-dose, non-contrast CT scan. The result is reported as an Agatston score, named after Arthur Agatston, who developed the scoring method in 1990.

Each calcified lesion above a density threshold of 130 Hounsfield units gets a weighted area score. The scanner sums these across every coronary segment. Zero means no calcified plaque was detected. That does not mean zero atherosclerosis, because soft, non-calcified plaque can exist without registering on this scan.

The Multi-Ethnic Study of Atherosclerosis (MESA), which enrolled 6,814 adults aged 45 to 84 and followed them for over 15 years, established the population-based percentile distributions that clinicians reference today [1]. A 55-year-old white male with a CAC of 150 sits at the 75th percentile, while the same score in a 55-year-old Black female would exceed the 90th percentile. These percentile cutoffs matter because the 2018 AHA/ACC Multisociety Cholesterol Guideline specifically recommends using age, sex, and race/ethnicity-adjusted percentiles alongside the raw Agatston number when making treatment decisions [2].

The scan takes about 10 minutes, requires no IV contrast, and delivers roughly 1 mSv of radiation, comparable to a two-view mammogram [3].

Who Should Get a CAC Scan (and Who Should Skip It)

The 2018 AHA/ACC guideline recommends CAC scoring for adults aged 40 to 75 whose 10-year atherosclerotic cardiovascular disease (ASCVD) risk falls between 5% and 20%, the so-called borderline and intermediate risk groups, when a statin decision is uncertain [2]. That range covers tens of millions of Americans.

CAC scanning is not recommended for three populations. Patients already on a statin gain little actionable data, because statin therapy itself can increase calcium density while stabilizing plaque. Patients with a 10-year ASCVD risk above 20% should start a statin regardless of their calcium score. And adults under 40 rarely have enough calcified plaque for the test to discriminate risk.

The 2019 ACC/AHA Primary Prevention Guideline reinforced this position. Dr. Roger Blumenthal, co-chair of that writing committee, stated: "CAC testing is most useful when the clinician and patient are engaged in a risk discussion and the decision about statin therapy is uncertain" [4]. The USPSTF issued an "I" (insufficient evidence) statement on CAC screening for the general population in 2018, but did not discourage its use in shared decision-making for borderline-risk individuals [5].

CAC of Zero: When You Can Safely Defer a Statin

A CAC score of zero is among the most powerful negative risk markers in cardiovascular medicine. Short sentence for emphasis: it changes everything.

In MESA, participants with a CAC of 0 had a 10-year coronary heart disease event rate of 1.1% to 1.7%, regardless of the number of traditional risk factors present [1]. A 2018 meta-analysis of 29,312 asymptomatic patients by Valenti et al., published in JACC: Cardiovascular Imaging, found that a CAC of 0 carried a 0.47% annualized event rate for major adverse cardiac events [6]. The 2018 AHA/ACC guideline explicitly states that "if the coronary artery calcium score is zero, treatment with statin therapy may be withheld or delayed" except in patients who smoke, have diabetes, or have a strong family history of premature ASCVD [2].

This is a concrete clinical shift. A 52-year-old woman with an LDL of 145 mg/dL and a 10-year ASCVD risk of 9% might sit in a gray zone by pooled cohort equation alone. If her CAC returns at zero, the guideline supports deferring statins and rechecking in 5 to 10 years. If it returns at 85, the calculus tips toward treatment.

The "power of zero" does have a shelf life. A 2022 analysis of MESA data showed that 25% of individuals with a baseline CAC of 0 developed incident coronary calcium within 5 years [7]. Repeat scanning after 5 to 10 years is reasonable for patients who deferred therapy based on a zero score.

CAC of 1 to 99: Mild Plaque, Meaningful Signal

A score between 1 and 99 confirms early atherosclerosis exists. This range approximately doubles the predicted 10-year ASCVD event rate compared to what the pooled cohort equation alone would estimate [2].

For patients already leaning toward statin therapy, a CAC of 1 to 99 often tips the scale. The guideline language is direct: a CAC score of 1 to 99 "favors statin therapy, especially in those ≥55 years of age" [2]. For a younger patient with a score of, say, 12, lifestyle optimization and serial monitoring may be appropriate, particularly if other risk enhancers (South Asian ancestry, family history, elevated lipoprotein(a), metabolic syndrome) are absent.

Dr. Michael Blaha, director of clinical research at the Johns Hopkins Ciccarone Center, has written: "Any calcium at all means the patient has crossed a biological threshold. The disease is present. The question is how aggressively to respond" [8]. A score of 1 in a 42-year-old carries more urgency than a score of 50 in a 70-year-old, because the age-adjusted percentile in the younger patient likely sits much higher.

Lipid targets in this range typically follow standard moderate-intensity statin dosing. Atorvastatin 10 to 20 mg or rosuvastatin 5 to 10 mg are common starting points. Advanced lipid testing, including lipoprotein(a), apolipoprotein B, and an NMR LDL particle count, may help refine the intensity of therapy, especially in younger patients with early calcium [9].

CAC of 100 to 299: The Statin Threshold

This range signals moderate plaque burden and, in the 2018 AHA/ACC framework, nearly always warrants pharmacotherapy. The guideline states that a CAC score of 100 or greater, or a CAC at or above the 75th percentile for age, sex, and race/ethnicity, "favors statin therapy" [2].

In the MESA cohort, participants with CAC 100 to 299 had a 10-year CHD event rate between 7.1% and 10.8%, placing them firmly in the range where the number needed to treat (NNT) for statins drops to approximately 30 to 40 over five years [1]. That NNT is comparable to treating stage 1 hypertension.

Beyond statins, a CAC above 100 should prompt a second look at blood pressure management. The 2017 ACC/AHA Hypertension Guideline lowered the treatment threshold to 130/80 mmHg for adults with high cardiovascular risk [10]. A CAC above 100 qualifies as high risk by most interpretive frameworks, so a patient with a systolic blood pressure of 135 mmHg and a CAC of 180 would have a stronger case for antihypertensive therapy than the same patient without calcium data.

Aspirin enters the conversation here as well, though cautiously. The 2019 ACC/AHA Primary Prevention Guideline generally weakened the recommendation for aspirin in primary prevention, but noted that adults aged 40 to 70 with higher ASCVD risk and no increased bleeding risk "might" benefit [4]. A CAC above 100 is one of the strongest objective markers supporting that conditional recommendation.

CAC of 300 or Above: Aggressive, Multimodal Treatment

A CAC above 300 places a patient in the highest-risk primary prevention category. The associated 10-year event rate in MESA exceeded 15% for most age and sex subgroups [1]. Treatment at this level is not optional. It is standard of care.

High-intensity statin therapy, meaning atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, is first-line [2]. If LDL cholesterol does not drop below 70 mg/dL on maximally tolerated statin therapy, the addition of ezetimibe 10 mg is the next step, supported by the IMPROVE-IT trial (N=18,144), which showed a 6.4% relative risk reduction in cardiovascular events when ezetimibe was added to simvastatin [11].

For patients with very high CAC scores (above 1,000 is not uncommon in older men) and LDL still above goal, PCSK9 inhibitors such as evolocumab or alirocumab become relevant. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced LDL by 59% and major cardiovascular events by 15% over a median of 2.2 years when added to statin therapy [12].

Blood pressure targets in this population should follow the SPRINT trial framework: a systolic target below 120 mmHg reduced the primary composite outcome by 25% in high-risk adults without diabetes [13]. A CAC above 300 places the patient squarely in the SPRINT-eligible risk category.

Antiplatelet therapy decisions for this group should be individualized, but the absolute benefit of low-dose aspirin is larger when baseline event rates are this high. The MESA investigators published a substudy showing that aspirin's net benefit (events prevented minus major bleeds caused) was positive only in patients with CAC above 100 [14].

Does the CAC Score Change Over Time?

Yes. CAC progresses at a median rate of 20% to 25% per year in untreated patients with baseline calcium present [15]. Statins do not slow calcium accrual. They may even modestly accelerate it by promoting plaque calcification, a process associated with plaque stabilization rather than increased risk. This is a common source of confusion.

A 2015 analysis from the St. Francis Heart Study showed that statin-treated patients experienced greater CAC progression than placebo-treated controls, yet had fewer clinical events [16]. The calcification was denser and more stable, representing a shift from soft, vulnerable plaque to hard, fibrous plaque. Clinicians should not discontinue statin therapy because a repeat CAC scan shows a higher number. That number may reflect therapeutic success.

Serial CAC scanning is not part of routine guidelines. The 2018 AHA/ACC statement does not recommend repeat scans at fixed intervals. Some experts, including Dr. Blaha, have proposed repeat scanning every 3 to 5 years for patients who deferred therapy based on a CAC of zero, and individual consideration for patients with initial scores between 1 and 99 [8].

CAC Scoring in Special Populations

The standard Agatston thresholds apply less cleanly in certain groups. Women develop coronary calcium approximately 10 to 15 years later than men, so a "low" absolute score in a premenopausal woman may carry more relative significance. The MESA percentile calculator accounts for this by producing sex-specific distributions [1].

Patients with type 2 diabetes present a particular challenge. The 2018 guideline recommends statins for all diabetic adults aged 40 to 75, regardless of CAC. A CAC of zero in a diabetic patient does not remove the statin indication, though it may support using moderate-intensity rather than high-intensity dosing [2].

South Asian adults carry higher cardiovascular risk at any given CAC level. A 2020 MESA substudy found that South Asian participants had a 1.5 to 2 times higher rate of cardiovascular events per unit of CAC compared to white participants [17]. This population-specific risk amplification is why the AHA lists South Asian ancestry as a standalone risk enhancer in the 2018 guideline.

Younger adults (under 45) with any detectable calcium represent an especially high-risk phenotype. A CAC of even 1 to 10 in a 38-year-old places that individual above the 90th percentile and warrants aggressive risk factor modification, including statin therapy, regardless of the calculated 10-year ASCVD risk [8].

Lifestyle and CAC: What the Evidence Actually Shows

No randomized trial has demonstrated that lifestyle changes reduce an existing CAC score. Calcium, once deposited in arterial walls, does not reverse with diet, exercise, or supplementation. The goal of lifestyle intervention is to slow progression and reduce the soft plaque burden that does not appear on the calcium scan.

Exercise has strong observational support. In MESA, participants in the highest quartile of physical activity had 25% slower CAC progression over 10 years than sedentary participants, even after adjustment for traditional risk factors [18]. Smoking cessation is associated with 30% slower CAC progression in the Heinz Nixdorf Recall Study (N=4,487) [19].

The Mediterranean diet, tested in PREDIMED (N=7,447), reduced composite cardiovascular events by 30% over 4.8 years, though the trial did not specifically track CAC progression [20]. Vitamin K2 supplementation has generated interest based on the Rotterdam Study observation that high dietary vitamin K2 intake was associated with reduced coronary calcification, but no randomized trial has confirmed this [21].

Patients who ask "how do I lower my CAC score" need honest counseling. The number will likely stay the same or go up. The objective is to prevent the next plaque rupture, not to erase existing calcium.

How to Read Your CAC Report

A standard CAC report includes the total Agatston score, scores for individual coronary arteries (left main, left anterior descending, left circumflex, right coronary), and often an age/sex percentile from the MESA reference database. Some reports include a volume score and a mass score, though the Agatston score remains the clinical standard.

Red flags in the report include: CAC above the 75th percentile for age and sex, a left main or proximal LAD score that constitutes more than 50% of the total (suggesting focal disease), and any score in a patient under 45. The report itself does not make treatment recommendations. That interpretation belongs to the ordering clinician, who must integrate the CAC data with the full clinical picture.